Nigeria seems to be cut out in a world where countries with robust capacities for research and development are reaping the gains of shifting healthcare investment towards home-based COVID-19 diagnostics kits.
In addition to the missed opportunity for huge fund flows into COVID-19 vaccine producti
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
